Fortress Biotech, Inc. — Form 8-K Summary
Event date: September 30, 2026. The report was signed October 1, 2026. This is an event filing, not a quarterly or annual financial report.
Business context and debt repayment
Fortress Biotech reported that it repaid in full the remaining principal under its senior secured credit agreement with Oaktree Fund Administration, LLC and participating lenders. The agreement originated in July 2024 with a $50.0 million facility and was amended in December 2025 and February 2026.
Financial impact disclosed
- Remaining principal repaid: $15.0 million.
- Accrued interest paid: approximately $435,000.
- Prepayment fee: $150,000.
- Other closing costs were also paid; the filing does not provide a clear value.
- The disclosed amounts total approximately $15.585 million, excluding other closing costs.
The filing provides no revenue, profit, cash flow, margin, or liquidity figures, and does not quantify the repayment’s impact on those measures.
Material change, outlook, and risks
Following repayment, all indebtedness under the Oaktree Agreement was deemed satisfied and paid in full, related liens and security interests were released and terminated, and the agreement automatically terminated. The filing provides no guidance, outlook, management commentary, or discussion of contingencies or other risks.
Investor facts to verify
- Confirm the repayment and release of the Oaktree-related liens in subsequent company disclosures.
- Review later financial statements for the cash impact, other closing costs, and any effect on liquidity or remaining debt.